Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative - PubMed (original) (raw)
. 1996 Jan 1;56(1):100-4.
Affiliations
- PMID: 8548747
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
E Buchdunger et al. Cancer Res. 1996.
Abstract
Oncogenic activation of Abl proteins due to structural modifications can occur as a result of viral transduction or chromosomal translocation. The tyrosine protein kinase activity of oncogenic Abl proteins is known to be essential for their transforming activity. Therefore, we have attempted to identify selective inhibitors of the Abl tyrosine protein kinase. Herein we describe an inhibitor (CGP 57148) of the Abl and platelet-derived growth factor (PDGF) receptor protein-tyrosine kinases from the 2-phenylaminopyrimidine class, which is highly active in vitro and in vivo. Submicromolar concentrations of the compound inhibited both v-Abl and PDGF receptor autophosphorylation and PDGF-induced c-fos mRNA expression selectively in intact cells. In contrast, ligand-induced growth factor receptor autophosphorylation in response to epidermal growth factor (EGF), insulin-like growth factor-I, and insulin showed no or weak inhibition by high concentrations of CGP 57148. c-fos mRNA expression induced by EGF, fibroblast growth factor, or phorbol ester was also insensitive to inhibition by CGP 57148. In antiproliferative assays, the compound was more than 30-100-fold more potent in inhibiting growth of v-abl-transformed PB-3c cells and v-sis-transformed BALB/c 3T3 cells relative to inhibition of EGF-dependent BALB/MK cells, interleukin-3-dependent FDC-P1 cells, and the T24 bladder carcinoma line. Furthermore, anchorage-independent growth of v-abl- and v-sis-transformed BALB/c 3T3 cells was inhibited potently by CGP 57148. When tested in vivo, CGP 57148 showed antitumor activity at tolerated doses against tumorigenic v-abl- and v-sis-transformed BALB/c 3T3 cells. In contrast, CGP 57148 had no antitumor activity when tested using src-transformed BALB/c 3T3 cells. These findings suggest that CGP 57148 may have therapeutic potential for the treatment of diseases that involve abnormal cellular proliferation induced by Abl protein-tyrosine kinase deregulation or PDGF receptor activation.
Similar articles
- Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Regenass U, Lydon NB. Buchdunger E, et al. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2558-62. doi: 10.1073/pnas.92.7.2558. Proc Natl Acad Sci U S A. 1995. PMID: 7708684 Free PMC article. Retracted. - Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
Major TC, Keiser JA. Major TC, et al. J Pharmacol Exp Ther. 1997 Oct;283(1):402-10. J Pharmacol Exp Ther. 1997. PMID: 9336349 - Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Buchdunger E, et al. J Pharmacol Exp Ther. 2000 Oct;295(1):139-45. J Pharmacol Exp Ther. 2000. PMID: 10991971 - Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N. Traxler P, et al. J Pharm Belg. 1997 Mar-Apr;52(2):88-96. J Pharm Belg. 1997. PMID: 9193132 Review. - Platelet derived growth factor/tyrosine kinase receptor mediated proliferation.
Benito M, Lorenzo M. Benito M, et al. Growth Regul. 1993 Sep;3(3):172-9. Growth Regul. 1993. PMID: 8220110 Review.
Cited by
- Stretching the structural envelope of imatinib to reduce β-amyloid production by modulating both β- and γ-secretase cleavages of APP.
Netzer WJ, Sinha A, Ghias M, Chang E, Gindinova K, Mui E, Seo JS, Sinha SC. Netzer WJ, et al. Front Chem. 2024 Oct 8;12:1381205. doi: 10.3389/fchem.2024.1381205. eCollection 2024. Front Chem. 2024. PMID: 39439934 Free PMC article. - Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma.
Liao S, Wang Q, Chen S, Huang Q, Zhou L, Liu H, He S, Zhou Z. Liao S, et al. J Transl Med. 2024 Aug 28;22(1):792. doi: 10.1186/s12967-024-05545-5. J Transl Med. 2024. PMID: 39198815 Free PMC article. - Structural screening and molecular simulation identify potential ligands against the K700E hot spot variant and functional pockets of SF3B1 to modulate splicing in myelodysplastic syndrome.
García R, Atis M, Cox A, Koduru P. García R, et al. Heliyon. 2024 Jun 10;10(12):e32729. doi: 10.1016/j.heliyon.2024.e32729. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 38975181 Free PMC article. - Targeting Protein Kinases to Protect Beta-Cell Function and Survival in Diabetes.
Dalle S. Dalle S. Int J Mol Sci. 2024 Jun 11;25(12):6425. doi: 10.3390/ijms25126425. Int J Mol Sci. 2024. PMID: 38928130 Free PMC article. Review. - IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension.
Gillies H, Chakinala MM, Dake BT, Feldman JP, Hoeper MM, Humbert M, Jing ZC, Langley J, McLaughlin VV, Niven RW, Rosenkranz S, Zhang X, Hill NS. Gillies H, et al. Pulm Circ. 2024 Mar 25;14(1):e12352. doi: 10.1002/pul2.12352. eCollection 2024 Jan. Pulm Circ. 2024. PMID: 38532768 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous